Penetrium Bioscience Inc. (KOSDAQ:187660)

South Korea · Delayed Price · Currency is KRW

4,410.00

+185.00 (4.38%)

At close: Aug 11, 2026

Penetrium Bioscience Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	9,745	9,745	13,790	14,883	13,978	13,120
Revenue Growth	-29.33%	-29.33%	-7.34%	6.47%	6.54%	28.55%
Gross Profit	57.97	57.97	3,185	4,323	7,205	7,400
Operating Income	-15,994	-15,994	-1,911	-754.74	2,091	3,531
Net Income	-20,096	-20,096	-2,970	266.5	1,923	3,775
Earnings Per Share	-475.02	-475.02	-70.21	6.22	48.00	109.72
EPS Growth	-	-	-	-87.05%	-56.25%	353.81%

Revenue by Segment

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Clinical Business Agency	9,292	9,292	13,489
Rental Business	429.83	429.83	266.71
Other Business	23.1	23.1	34.62
Total	9,745	9,745	13,790

Cash & Debt

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Investments	5,843	5,843	18,974	35,070	30,770	14,700
Total Debt	9,288	9,288	690.36	641.31	335.09	344.01
Net Cash (Debt)	-3,445	-3,445	18,283	34,429	30,435	14,356
Net Cash Growth	-	-	-46.89%	13.12%	112.01%	58.13%
Net Cash Per Share	-81.43	-81.43	432.17	762.19	763.49	417.29

Cash Flow & CapEx

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Cash Flow	-14,292	-14,292	-3,078	903.74	689.21	5,323
Capital Expenditures	-53.88	-53.88	-12,435	-1,417	-1,074	-75.87
Free Cash Flow	-14,346	-14,346	-15,513	-512.83	-384.44	5,247
Free Cash Flow Growth	-	-	-	-	-	335.53%

Margins

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Gross Margin	0.60%	0.60%	23.09%	29.05%	51.55%	56.41%
Operating Margin	-164.13%	-164.13%	-13.86%	-5.07%	14.96%	26.91%
Pretax Margin	-187.09%	-187.09%	-12.88%	0.51%	15.52%	34.99%
Profit Margin	-206.22%	-206.22%	-21.54%	1.79%	13.76%	28.77%
FCF Margin	-147.22%	-147.22%	-112.49%	-3.45%	-2.75%	40.00%

Valuation

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug '26 Aug 12, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
PE Ratio	-	-	-	163.51	67.47	-
PS Ratio	24.78	7.16	3.20	2.93	9.28	-